Your shopping cart is currently empty

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $82 | In Stock | In Stock | |
| 5 mg | $195 | In Stock | In Stock | |
| 10 mg | $285 | In Stock | In Stock | |
| 25 mg | $449 | In Stock | In Stock | |
| 50 mg | $601 | In Stock | In Stock | |
| 100 mg | $805 | In Stock | In Stock | |
| 200 mg | $1,090 | - | In Stock |
| Description | Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots. |
| Targets&IC50 | TXA2 receptor:apr 10 nM, TXA2 synthase:appr 10 nM |
| In vitro | Terbogrel inhibits collagen-induced platelet aggregation in human platelet-rich plasma and whole blood (IC50: 310 ± 18 nM (n = 8) and 52 ± 20 nM (n = 6), respectively). Terbogrel (1 μM) fully inhibits U46619-induced platelet aggregation (IC50: 10 nM). Pretreatment of platelets with terbogrel (1 μM) completely inhibits thrombin-induced thromboxane A2 formation (2±1 ng/mL) but does not result in any inhibition of platelet aggregation. Terbogrel blocks the thromboxane A2/endoperoxide receptor on washed human platelets (IC50: 11 ± 6 nM (n = 2) and IC50: 38 ± 1 nM (n = 15) in platelet-rich plasma).[1][2] |
| In vivo | Terbogrel (10 mg/kg, p.o.) is rapidly and well (90%) absorbed with a systemic availability of about 30% in rats. Terbogrel (0.1-3.0 mg/kg) shows an impressive antithrombotic efficacy in rabbits.[2] |
| Synonyms | BIBV 308SE |
| Molecular Weight | 405.49 |
| Formula | C23H27N5O2 |
| Cas No. | 149979-74-8 |
| Smiles | C(=C\CCCC(O)=O)(\C1=CC(N=C(NC(C)(C)C)NC#N)=CC=C1)/C=2C=CC=NC2 |
| Relative Density. | 1.13g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (67.82 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.